Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study | Trials | Full Text

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study | Trials | Full Text

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study

Despite the chronicled success of low-density lipoprotein cholesterol (LDLc)-lowering statin therapy, substantial residual cardiovascular (CV) disease risk remains a problem worldwide, highlighting the need to...

Authors:Taek-Geun Kwon, Albert Youngwoo Jang, Sang Wook Kim, Young Joon Hong, Jang-Ho Bae, Sung Yun Lee, Sang-Hyun Kim and Seung Hwan Han

Citation:Trials 2020 21:353

Content type:Study protocol

Published on: 22 April 2020

• ViewFull Text
 
• ViewPDF